Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Ultrasound and Clinical Preoperative Characteristics for Discrimination Between Ovarian Metastatic Colorectal Cancer and Primary Ovarian Cancer: A Case-Control Study.

Stukan M, Alcazar JL, Gębicki J, Epstein E, Liro M, Sufliarska A, Szubert S, Guerriero S, Braicu EI, Szajewski M, Pietrzak-Stukan M, Fischerova D.

Diagnostics (Basel). 2019 Dec 1;9(4). pii: E210. doi: 10.3390/diagnostics9040210.

2.

EZH2 Loss Drives Resistance to Carboplatin and Paclitaxel in Serous Ovarian Cancers Expressing ATM.

Naskou J, Beiter Y, van Rensburg R, Honisch E, Rudelius M, Schlensog M, Gottstein J, Walter L, Braicu EI, Sehouli J, Darb-Esfahani S, Staebler A, Hartkopf AD, Brucker S, Wallwiener D, Beyer I, Niederacher D, Fehm T, Templin MF, Neubauer H.

Mol Cancer Res. 2019 Nov 8. doi: 10.1158/1541-7786.MCR-19-0141. [Epub ahead of print]

PMID:
31704732
3.

Dual targeting of estrogen receptor α and estrogen-related receptor α: a novel endocrine therapy for endometrial cancer.

Mao X, Dong B, Gao M, Ruan G, Huang M, Braicu EI, Sehouli J, Sun P.

Onco Targets Ther. 2019 Aug 20;12:6757-6767. doi: 10.2147/OTT.S216146. eCollection 2019.

4.

Incidence and Pattern of Spread of Lymph Node Metastasis in Patients With Low-grade Serous Ovarian Cancer.

Wafa M, Braicu EI, Muallem MZ, Richter R, Taube E, Sehouli J, Grabowski JP.

Anticancer Res. 2019 Oct;39(10):5617-5621. doi: 10.21873/anticanres.13757.

PMID:
31570458
5.

Dilution of Molecular-Pathologic Gene Signatures by Medically Associated Factors Might Prevent Prediction of Resection Status After Debulking Surgery in Patients With Advanced Ovarian Cancer.

Heitz F, Kommoss S, Tourani R, Grandelis A, Uppendahl L, Aliferis C, Burges A, Wang C, Canzler U, Wang J, Belau A, Prader S, Hanker L, Ma S, Ataseven B, Hilpert F, Schneider S, Sehouli J, Kimmig R, Kurzeder C, Schmalfeldt B, Braicu EI, Harter P, Dowdy SC, Winterhoff BJ, Pfisterer J, du Bois A.

Clin Cancer Res. 2020 Jan 1;26(1):213-219. doi: 10.1158/1078-0432.CCR-19-1741. Epub 2019 Sep 16.

PMID:
31527166
6.

Discovery and Validation of Novel Biomarkers for Detection of Epithelial Ovarian Cancer.

Kulbe H, Otto R, Darb-Esfahani S, Lammert H, Abobaker S, Welsch G, Chekerov R, Schäfer R, Dragun D, Hummel M, Leser U, Sehouli J, Braicu EI.

Cells. 2019 Jul 12;8(7). pii: E713. doi: 10.3390/cells8070713.

7.

Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.

Canaz E, Grabowski JP, Richter R, Braicu EI, Chekerov R, Sehouli J.

Gynecol Oncol. 2019 Sep;154(3):539-546. doi: 10.1016/j.ygyno.2019.06.014. Epub 2019 Jun 21.

PMID:
31230821
8.

Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer.

Kreuzinger C, von der Decken I, Wolf A, Gamperl M, Koller J, Karacs J, Pfaffinger S, Bartl T, Reinthaller A, Grimm C, Singer CF, Braicu EI, Cunnea P, Gourley C, Smeets D, Boeckx B, Lambrechts D, Perco P, Horvat R, Berns EMJJ, Cacsire Castillo-Tong D.

Cancer Lett. 2019 Sep 10;459:1-12. doi: 10.1016/j.canlet.2019.05.032. Epub 2019 May 28.

PMID:
31150822
9.

Sialic Acid Linkage Analysis Refines the Diagnosis of Ovarian Cancer.

Dědová T, Braicu EI, Sehouli J, Blanchard V.

Front Oncol. 2019 Apr 11;9:261. doi: 10.3389/fonc.2019.00261. eCollection 2019.

10.

Interrelations of Sphingolipid and Lysophosphatidate Signaling with Immune System in Ovarian Cancer.

Meshcheryakova A, Svoboda M, Jaritz M, Mungenast F, Salzmann M, Pils D, Cacsire Castillo-Tong D, Hager G, Wolf A, Braicu EI, Sehouli J, Lambrechts S, Vergote I, Mahner S, Birner P, Zimmermann P, Brindley DN, Heinze G, Zeillinger R, Mechtcheriakova D.

Comput Struct Biotechnol J. 2019 Apr 10;17:537-560. doi: 10.1016/j.csbj.2019.04.004. eCollection 2019.

11.

Chronic Chlamydia infection in human organoids increases stemness and promotes age-dependent CpG methylation.

Kessler M, Hoffmann K, Fritsche K, Brinkmann V, Mollenkopf HJ, Thieck O, Teixeira da Costa AR, Braicu EI, Sehouli J, Mangler M, Berger H, Meyer TF.

Nat Commun. 2019 Mar 18;10(1):1194. doi: 10.1038/s41467-019-09144-7.

12.

Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium.

Guan J, Darb-Esfahani S, Richter R, Taube ET, Ruscito I, Mahner S, Woelber L, Prieske K, Concin N, Vergote I, Van Nieuwenhuysen E, Achimas-Cadariu P, Glajzer J, Woopen H, Stanske M, Kulbe H, Denkert C, Sehouli J, Braicu EI.

J Cancer Res Clin Oncol. 2019 Apr;145(4):1063-1073. doi: 10.1007/s00432-019-02877-4. Epub 2019 Feb 27.

PMID:
30810838
13.

Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network.

Sehouli J, Braicu EI, Richter R, Denkert C, Jank P, Jurmeister PS, Kunze CA, Budczies J, Darb-Esfahani S, Schmitt WD, Traut A, Grabowski J, Taube ET, Plett H.

Hum Pathol. 2019 Mar;85:299-308. doi: 10.1016/j.humpath.2018.10.020. Epub 2018 Nov 11.

PMID:
30428389
14.

Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism.

Niemi RJ, Braicu EI, Kulbe H, Koistinen KM, Sehouli J, Puistola U, Mäenpää JU, Hilvo M.

Br J Cancer. 2018 Oct;119(7):847-854. doi: 10.1038/s41416-018-0270-z. Epub 2018 Oct 8.

15.

Potential role of the HOXD8 transcription factor in cisplatin resistance and tumour metastasis in advanced epithelial ovarian cancer.

Sun P, Song Y, Liu D, Liu G, Mao X, Dong B, Braicu EI, Sehouli J.

Sci Rep. 2018 Sep 7;8(1):13483. doi: 10.1038/s41598-018-31030-3.

16.

Novel endocrine therapeutic strategy in endometrial carcinoma targeting estrogen-related receptor α by XCT790 and siRNA.

Sun P, Mao X, Gao M, Huang M, Chen L, Ruan G, Huang W, Braicu EI, Sehouli J.

Cancer Manag Res. 2018 Aug 10;10:2521-2535. doi: 10.2147/CMAR.S168043. eCollection 2018.

17.

Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

Chekerov R, Hilpert F, Mahner S, El-Balat A, Harter P, De Gregorio N, Fridrich C, Markmann S, Potenberg J, Lorenz R, Oskay-Oezcelik G, Schmidt M, Krabisch P, Lueck HJ, Richter R, Braicu EI, du Bois A, Sehouli J; NOGGO; AGO TRIAS Investigators.

Lancet Oncol. 2018 Sep;19(9):1247-1258. doi: 10.1016/S1470-2045(18)30372-3. Epub 2018 Aug 9.

PMID:
30100379
18.

Clinical Outcome After Completion Surgery in Patients With Ovarian Cancer: The Charite Experience.

Babayeva A, Braicu EI, Grabowski JP, Gasimli K, Richter R, Muallem MZ, Sehouli J.

Int J Gynecol Cancer. 2018 Oct;28(8):1491-1497. doi: 10.1097/IGC.0000000000001328.

PMID:
30095708
19.

Preoperative CA-125 Value as a Predictive Factor for Postoperative Outcome in First Relapse of Platinum-sensitive Serous Ovarian Cancer.

Parashkevova A, Sehouli J, Richter R, Dimitrova D, Braicu EI, Muallem MZ.

Anticancer Res. 2018 Aug;38(8):4865-4870. doi: 10.21873/anticanres.12799.

PMID:
30061261
20.

Morphology and tumour-infiltrating lymphocytes in high-stage, high-grade serous ovarian carcinoma correlated with long-term survival.

Darb-Esfahani S, Kolaschinski I, Trillsch F, Mahner S, Concin N, Vergote I, Van Nieuwenhuysen E, Achimas-Cadariu P, Glajzer J, Woopen H, Wienert S, Taube ET, Stanske M, Kulbe H, Denkert C, Sehouli J, Braicu EI.

Histopathology. 2018 Dec;73(6):1002-1012. doi: 10.1111/his.13711. Epub 2018 Oct 7.

PMID:
30007074
21.

Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).

Ruscito I, Cacsire Castillo-Tong D, Vergote I, Ignat I, Stanske M, Vanderstichele A, Glajzer J, Kulbe H, Trillsch F, Mustea A, Kreuzinger C, Benedetti Panici P, Gourley C, Gabra H, Nuti M, Taube ET, Kessler M, Sehouli J, Darb-Esfahani S, Braicu EI.

Br J Cancer. 2018 Aug;119(3):330-338. doi: 10.1038/s41416-018-0157-z. Epub 2018 Jun 29.

22.

Proteomic and Bioinformatic Studies for the Characterization of Response to Pemetrexed in Platinum Drug Resistant Ovarian Cancer.

Severi L, Losi L, Fonda S, Taddia L, Gozzi G, Marverti G, Magni F, Chinello C, Stella M, Sheouli J, Braicu EI, Genovese F, Lauriola A, Marraccini C, Gualandi A, D'Arca D, Ferrari S, Costi MP.

Front Pharmacol. 2018 May 8;9:454. doi: 10.3389/fphar.2018.00454. eCollection 2018.

23.

The Role of PAR1 Autoantibodies in Patients with Primary Epithelial Ovarian Cancer.

Kreienbring K, Franz A, Richter R, Dragun D, Heidecke H, Müller D, Mentze M, Dechend R, Sehouli J, Braicu EI.

Anticancer Res. 2018 Jun;38(6):3619-3625. doi: 10.21873/anticanres.12636.

PMID:
29848718
24.

The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer: A meta-analysis.

Ruscito I, Darb-Esfahani S, Kulbe H, Bellati F, Zizzari IG, Rahimi Koshkaki H, Napoletano C, Caserta D, Rughetti A, Kessler M, Sehouli J, Nuti M, Braicu EI.

Gynecol Oncol. 2018 Jul;150(1):151-157. doi: 10.1016/j.ygyno.2018.05.006. Epub 2018 May 10.

PMID:
29753392
25.

Immunobiology of Solid Cancers: Cellular and Molecular Pathways as Potential Diagnostic and Therapeutic Targets.

Ruscito I, Braicu EI, Gasparri ML, Zizzari IG.

Biomed Res Int. 2018 Mar 1;2018:6532019. doi: 10.1155/2018/6532019. eCollection 2018. No abstract available.

26.

Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.

Caumanns JJ, Berns K, Wisman GBA, Fehrmann RSN, Tomar T, Klip H, Meersma GJ, Hijmans EM, Gennissen AMC, Duiker EW, Weening D, Itamochi H, Kluin RJC, Reyners AKL, Birrer MJ, Salvesen HB, Vergote I, van Nieuwenhuysen E, Brenton J, Braicu EI, Kupryjanczyk J, Spiewankiewicz B, Mittempergher L, Bernards R, van der Zee AGJ, de Jong S.

Clin Cancer Res. 2018 Aug 15;24(16):3928-3940. doi: 10.1158/1078-0432.CCR-17-3060. Epub 2018 Apr 23.

27.

Correction: Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers.

Gschwantler-Kaulich D, Weingartshofer S, Rappaport-Fürhauser C, Zeillinger R, Pils D, Muhr D, Braicu EI, Kastner MT, Tan YY, Semmler L, Sehouli J, Singer CF.

PLoS One. 2018 Apr 17;13(4):e0196142. doi: 10.1371/journal.pone.0196142. eCollection 2018.

28.

Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium.

Obermayr E, Bednarz-Knoll N, Orsetti B, Weier HU, Lambrechts S, Castillo-Tong DC, Reinthaller A, Braicu EI, Mahner S, Sehouli J, Vergote I, Theillet C, Zeillinger R, Brandt B.

Oncotarget. 2017 Nov 16;8(63):106415-106428. doi: 10.18632/oncotarget.22468. eCollection 2017 Dec 5.

29.

High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism.

Braicu EI, Darb-Esfahani S, Schmitt WD, Koistinen KM, Heiskanen L, Pöhö P, Budczies J, Kuhberg M, Dietel M, Frezza C, Denkert C, Sehouli J, Hilvo M.

Oncotarget. 2017 Oct 26;8(61):102912-102922. doi: 10.18632/oncotarget.22076. eCollection 2017 Nov 28.

30.

Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers.

Gschwantler-Kaulich D, Weingartshofer S, Rappaport-Fürhauser C, Zeillinger R, Pils D, Muhr D, Braicu EI, Kastner MT, Tan YY, Semmler L, Sehouli J, Singer CF.

PLoS One. 2017 Dec 15;12(12):e0189641. doi: 10.1371/journal.pone.0189641. eCollection 2017. Erratum in: PLoS One. 2018 Apr 17;13(4):e0196142.

31.

The Impact of Surgical Staging on the Prognosis of Mucinous Borderline Tumors of the Ovaries: A Multicenter Study.

Gungorduk K, Asicioglu O, Braicu EI, Almuheimid J, Gokulu SG, Cetinkaya N, Gungor T, Pakay G, Telli EU, Cuylan ZF, Toptas T, Bilgi A, Ozyurt R, Agacayak E, Ozdemir A, Yildirim N, Taskin S, Oge T, Erol O, Akman L, Turan A, Icen MS, Senol T, Ovali OI, Yucesoy B, Gungorduk O, Temizkan O, Sanci M, Simsek T, Meydanli MM, Harma M, Yasar L, Uysal AD, Karateke A, Ortac F, Ozalp SS, Sehouli J, Muallem MZ.

Anticancer Res. 2017 Oct;37(10):5609-5616.

PMID:
28982877
32.

A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer.

Kreuzinger C, Geroldinger A, Smeets D, Braicu EI, Sehouli J, Koller J, Wolf A, Darb-Esfahani S, Joehrens K, Vergote I, Vanderstichele A, Boeckx B, Lambrechts D, Gabra H, Wisman GBA, Trillsch F, Heinze G, Horvat R, Polterauer S, Berns E, Theillet C, Cacsire Castillo-Tong D.

Clin Cancer Res. 2017 Dec 15;23(24):7621-7632. doi: 10.1158/1078-0432.CCR-17-1159. Epub 2017 Oct 2.

33.

Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients: A Study of the Tumor Bank Ovarian Cancer Consortium.

Sun T, Ruscito I, Dimitrova D, Chekerov R, Kulbe H, Baron U, Blanchard V, Panici PB, Darb-Esfahani S, Sehouli J, Olek S, Braicu EI.

Int J Gynecol Cancer. 2017 Oct;27(8):1658-1665. doi: 10.1097/IGC.0000000000001071.

PMID:
28691938
34.

Preoperative CA-125 Values as a Predictive Factor for the Postoperative Outcome in Primary Serous Ovarian Cancer.

Muallem MZ, Parashkevova A, Almuheimid J, Richter R, Diab Y, Braicu EI, Sehouli J.

Anticancer Res. 2017 Jun;37(6):3157-3161.

PMID:
28551658
35.

Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.

Ruscito I, Cacsire Castillo-Tong D, Vergote I, Ignat I, Stanske M, Vanderstichele A, Ganapathi RN, Glajzer J, Kulbe H, Trillsch F, Mustea A, Kreuzinger C, Benedetti Panici P, Gourley C, Gabra H, Kessler M, Sehouli J, Darb-Esfahani S, Braicu EI.

Eur J Cancer. 2017 Jul;79:214-225. doi: 10.1016/j.ejca.2017.04.016. Epub 2017 May 16.

36.

The ascites N-glycome of epithelial ovarian cancer patients.

Biskup K, Braicu EI, Sehouli J, Tauber R, Blanchard V.

J Proteomics. 2017 Mar 22;157:33-39. doi: 10.1016/j.jprot.2017.02.001. Epub 2017 Feb 8.

PMID:
28188862
37.

Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses.

Vanderstichele A, Busschaert P, Smeets D, Landolfo C, Van Nieuwenhuysen E, Leunen K, Neven P, Amant F, Mahner S, Braicu EI, Zeilinger R, Coosemans A, Timmerman D, Lambrechts D, Vergote I.

Clin Cancer Res. 2017 May 1;23(9):2223-2231. doi: 10.1158/1078-0432.CCR-16-1078. Epub 2016 Nov 14.

38.
39.

Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer.

Flanagan JM, Wilson A, Koo C, Masrour N, Gallon J, Loomis E, Flower K, Wilhelm-Benartzi C, Hergovich A, Cunnea P, Gabra H, Braicu EI, Sehouli J, Darb-Esfahani S, Vanderstichele A, Vergote I, Kreuzinger C, Castillo-Tong DC, Wisman GBA, Berns EM, Siddiqui N, Paul J, Brown R.

Clin Cancer Res. 2017 May 1;23(9):2213-2222. doi: 10.1158/1078-0432.CCR-16-1754. Epub 2016 Sep 23.

40.

Predictive and Prognostic Value of sPRR in Patients with Primary Epithelial Ovarian Cancer.

Kreienbring K, Franz A, Richter R, Dragun D, Heidecke H, Dechend R, Muller DN, Sehouli J, Braicu EI.

Anal Cell Pathol (Amst). 2016;2016:6845213. Epub 2016 Aug 31.

41.

Diaphragmatic Surgery in Advanced Ovarian, Tubal and Peritoneal Cancer. A 7-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.

Muallem MZ, Almuheimid J, Richter R, Braicu EI, Osman S, Sehouli J.

Anticancer Res. 2016 Sep;36(9):4707-13.

PMID:
27630317
42.

Y-box protein-1/p18 as novel serum marker for ovarian cancer diagnosis: A study by the Tumor Bank Ovarian Cancer (TOC).

Rohr I, Braicu EI, En-Nia A, Heinrich M, Richter R, Chekerov R, Dechend R, Heidecke H, Dragun D, Schäfer R, Gorny X, Lindquist JA, Brandt S, Sehouli J, Mertens PR.

Cytokine. 2016 Sep;85:157-64. doi: 10.1016/j.cyto.2016.06.021. Epub 2016 Jun 29.

PMID:
27371774
43.

Sentinel Node Mapping in Cervical and Endometrial Cancer: Indocyanine Green Versus Other Conventional Dyes-A Meta-Analysis.

Ruscito I, Gasparri ML, Braicu EI, Bellati F, Raio L, Sehouli J, Mueller MD, Panici PB, Papadia A.

Ann Surg Oncol. 2016 Oct;23(11):3749-3756. doi: 10.1245/s10434-016-5236-x. Epub 2016 May 9. Review.

PMID:
27160526
44.

Corrigendum to "Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer" [Eur J Cancer 53 (2016) 51-64].

Lambrechts S, Smeets D, Moisse M, Braicu EI, Vanderstichele A, Zhao H, Van Nieuwenhuysen E, Berns E, Sehouli J, Zeillinger R, Darb-Esfahani S, Castillo-Tong DC, Lambrechts D, Vergote I.

Eur J Cancer. 2016 Jun;60:226. doi: 10.1016/j.ejca.2016.03.007. Epub 2016 Apr 19. No abstract available.

PMID:
27106403
45.

Statistical controversies in clinical research: the importance of importance.

Gleiss A, Zeillinger R, Braicu EI, Trillsch F, Vergote I, Schemper M.

Ann Oncol. 2016 Jul;27(7):1185-9. doi: 10.1093/annonc/mdw159. Epub 2016 Apr 6.

46.

Role of IGF-I in Primary Ovarian Cancer - A Study of the OVCAD European Consortium.

Rohr I, Zeillinger R, Heinrich M, Concin N, Vergote I, Nassir M, Mahner S, VAN Nieuwenhuysen E, Trillsch F, Cacsire-Tong D, Chekerov R, Sehouli J, Braicu EI.

Anticancer Res. 2016 Mar;36(3):1015-22.

PMID:
26976992
47.

PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives.

Sehouli J, Braicu EI, Chekerov R.

Geburtshilfe Frauenheilkd. 2016 Feb;76(2):164-169. Review.

48.

Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.

Gasimli K, Braicu EI, Nassir M, Richter R, Babayeva A, Chekerov R, Darb-Esfahani S, Sehouli J, Muallem MZ.

Ann Surg Oncol. 2016 Apr;23(4):1279-86. doi: 10.1245/s10434-015-4959-4. Epub 2016 Jan 29.

PMID:
26832880
49.

Acute-phase glycoprotein N-glycome of ovarian cancer patients analyzed by CE-LIF.

Weiz S, Wieczorek M, Schwedler C, Kaup M, Braicu EI, Sehouli J, Tauber R, Blanchard V.

Electrophoresis. 2016 Jun;37(11):1461-7. doi: 10.1002/elps.201500518. Epub 2016 Feb 17.

PMID:
26763099
50.

Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.

Lambrechts S, Smeets D, Moisse M, Braicu EI, Vanderstichele A, Zhao H, Van Nieuwenhuysen E, Berns E, Sehouli J, Zeillinger R, Darb-Esfahani S, Cacsire Castillo-Tong D, Lambrechts D, Vergote I.

Eur J Cancer. 2016 Jan;53:51-64. doi: 10.1016/j.ejca.2015.11.001. Epub 2015 Dec 13.

PMID:
26693899

Supplemental Content

Loading ...
Support Center